Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2022 07:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
November 29, 2021 08:01 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference

HOUSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
November 04, 2021 16:05 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Cash and Cash Equivalents of $31.9 Million Sufficient to Fund Completion of Ongoing Clinical Trials for Lead Drug Candidate Seclidemstat Added Five New Clinical Sites to Sarcoma Trial; 13 Active...
October 26, 2021 08:01 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress

HOUSTON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
October 07, 2021 09:05 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals and Nationwide Children’s Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

HOUSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
September 28, 2021 07:01 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas

HOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
September 27, 2021 08:03 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference

HOUSTON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
August 12, 2021 14:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational

HOUSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
July 29, 2021 07:33 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results

HOUSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...